Definium Therapeutics, Inc. (DFTX) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Definium Therapeutics, Inc. (DFTX) posted $0 in revenue for fiscal 2025, with a net loss of $183.79M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Definium Therapeutics, Inc.
Definium Therapeutics, Inc. has grown revenue from $0 to $0 over the last 6 fiscal years.
It carries about $40.58M of total debt.
The one thing worth a second look in the filings is debt with negative operating cash flow.
Synthesised from Definium Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Definium Therapeutics, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-33.94M | $-93.04M | $-56.80M | $-95.73M | $-108.68M | $-183.79M |
| Net margin | — | — | — | — | — | — |
Source: Definium Therapeutics, Inc. SEC filings (10-K).
Definium Therapeutics, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Debt with negative operating cash flowCarries $40.6M of debt while last year's operating cash flow was negative ($-131.6M).
Explore 6 years of Definium Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DFTX in your portfolio →
Definium Therapeutics, Inc. financial history by metric
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Definium Therapeutics, Inc. — frequently asked questions
What is Definium Therapeutics, Inc.'s revenue?
Definium Therapeutics, Inc. (DFTX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Definium Therapeutics, Inc. profitable?
No — DFTX reported a net loss of $-183.79M in fiscal 2025.
What is DFTX's P/E ratio?
Definium Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Definium Therapeutics, Inc. have?
As of fiscal year 2025, DFTX carried roughly $40.58M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Definium Therapeutics, Inc.'s market cap?
Definium Therapeutics, Inc. (DFTX) has a market capitalization of about $2.60B, based on the latest data in our nightly-refreshed cache.
When does Definium Therapeutics, Inc.'s fiscal year end?
DFTX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Definium Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.